openPR Logo
Press release

Investigation announced for Long-Term Investors in Moderna, Inc. (NASDAQ: MRNA) shares

09-15-2020 08:19 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Moderna, Inc. (NASDAQ: MRNA) shares over potential wrongdoing at Moderna, Inc.

An investigation on behalf of investors in Moderna, Inc. (NASDAQ: MRNA) shares over potential wrongdoing at Moderna, Inc.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Moderna, Inc.

Investors who purchased shares of Moderna, Inc. (NASDAQ: MRNA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Moderna directors breached their fiduciary duties and caused damage to the company and its shareholders.

Cambridge, MA based Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

On May 18, 2020, Moderna, Inc a announced Phase 1 trial results for a candidate vaccine for COVID-19 under development by the Company, indicating that the candidate appeared to generate an immune response similar to the response seen in individuals who have been infected by the virus and recovered. Specifically, Moderna reported that eight patients who received two doses of the vaccine at the lowest and middle doses tested - 25 and 100 micrograms - developed neutralizing antibodies to the virus at levels similar to people who had recovered from infection.

Shares of Moderna, Inc. (NASDAQ: MRNA) rose to $87.00 per share on May 18, 2020.

In the days following Moderna’s announcement, the Company’s announcement was the subject of skeptical commentary from multiple sources. For example, on May 19, 2020, an article was published entitled "Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine," which noted, in part, that "[w]hile Moderna blitzed the media, it revealed very little information - and most of what it did disclose were words, not data."

Shares of Moderna, Inc. (NASDAQ: MRNA) declined to $57.05 per share on May 26, 2020.

Those who purchased shares of Moderna, Inc. (NASDAQ: MRNA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Moderna, Inc. (NASDAQ: MRNA) shares here

News-ID: 2134796 • Views: 485

More Releases from Shareholders Foundation

Investigation for Long-Term investors in NASDAQ: KNDI shares over possible Wrong …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Kandi Technologies Group Inc. Investors who are current long term investors in Kandi Technologies Group Inc (NASDAQ: KNDI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: KNDI stocks follows a lawsuit filed
Investigation for Long-Term Investors in shares of Kirby Corporation (NYSE: KEX) …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kirby Corporation. Investors who purchased shares of Kirby Corporation (NYSE: KEX) s have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Kirby Corporation directors breached their fiduciary duties and caused damage to the company and its shareholders. Houston, TX based
Investigation announced for Investors in shares of Builders FirstSource, Inc. (N …
An investigation was announced concerning whether the takeover of Builders FirstSource, Inc. is unfair to NASDAQ: BLDR stockholders. Investors who purchased shares of Builders FirstSource, Inc. (NASDAQ: BLDR) and currently hold any of those NASDAQ: BLDR shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of Builders FirstSource, Inc. breached their
Investigation for Investors in ANSDAQ: ENDP over possible Wrongdoing at Endo Int …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Endo International plc. Investors who are current long term investors in Endo International plc (NASDAQ: ENDP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: ENDP stocks follows a lawsuit filed against Endo

All 5 Releases


More Releases for Moderna

Coronavirus (COVID-19) Treatment Market SWOT Analysis by Key Players: Moderna Th …
HTF MI recently added Global Coronavirus (COVID-19) Treatment Market Study that gives deep analysis of current scenario of the Market size, demand, growth, trends, and forecast. Revenue for Coronavirus (COVID-19) Treatment Market has grown substantially over the five years to 2019 as a result of strengthening macroeconomic conditions and healthier demand, however with current economic slowdown and Face-off with COVID-19 Industry Players are seeing Big Impact in operations and identifying
Cytomegalovirus (CMV) Vaccines Market Is Set to Experience Revolutionary Growth …
At present, there is no vaccine against this virus still, researchers and experts are focusing on understanding the correlates of defensive immunity for fetus and information about few major components of maternal immune response required for prevention of transplacental transmission. This infection is majorly prevalent in the newborns in the United States. The progress of the ongoing COVID-19 pandemic, worldwide has substantially impact several healthcare domains and other areas of
Coronavirus Vaccine Investment Market Still Going Strong | AbbVie, Novavax, Pfiz …
The coronavirus (COVID-19) disease is affecting 210 countries and territories around the world and 2 international conveyances. The major players are investing in the research and development activities of the coronavirus vaccine. In the race to develop a vaccine to end the COVID-19 pandemic, governments, charities and Big Pharma firms are sinking billions of dollars into bets with extraordinarily low odds of success. They are ensuring quick development of new
Cardiac Safety Services Market Seeking Excellent Growth| Sanofi, Amicus Therapeu …
Cardiac Safety Services Market (COVID-19 Impact Analysis) 2020 analysis document is sure to assist in achieving one of the most important goals of every business i.e. gaining maximum return on investment (ROI). B usinesses can get important market insights in a cost effective way with this comprehensive business report. This market study encompasses a market attractiveness analysis, wherein each segment is benchmarked based on its market size, demand, trends, growth
mRNA Vaccine Market Competitive Share & Forecast 2019| Moderna Therapeutics, Cur …
The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global mRNA Vaccine market. It sheds light on how the global mRNA Vaccine Market is expected to grow during the course of the forecast period. With SWOT analysis and Porter’s Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global mRNA Vaccine market and different
mRNA Vaccine Market Professional Analysis Report 2019| Moderna Therapeutics, Cur …
Los Angeles, United State, Mar 5, 2019-The research report focuses on target groups of customers to help players to effectively market their products and achieve strong sales in the global mRNA Vaccine market. It segregates useful and relevant market information as per the business needs of players. Readers are provided with validated and revalidated market forecast figures such as CAGR, mRNA Vaccine market revenue, production, consumption, and market share. Our